About Aprea Therapeutics
Aprea Therapeutics is a publicly listed company based in Boston (United States) founded in 2003. Small molecule therapeutics are developed to target tumor suppressor proteins. It operates on a HealthTech model. Aprea Therapeutics has raised $113.17 million across 6 funding rounds from investors including HHS, Janus Henderson Investors and Karolinska Development. The company has 8 employees. Aprea Therapeutics has completed 1 acquisition, including Atrin Pharma. Aprea Therapeutics offers products and services including DDR-Targeted Therapeutics and Small Molecule Inhibitors. Its focus areas include Biotechnology and Cancer Therapeutics. Its competitors include Revolution Medicines, Blueprint Medicines and Syndax; 3 of its 3 listed competitors have raised funding.
Company details
Aprea Therapeutics is engaged in the development of novel DNA Damage Response (DDR)-targeted cancer therapeutics. The company utilizes precision medicine to match treatments with specific genetic mutations in cancer, aiming to enhance effectiveness and reduce side effects. Their portfolio includes small molecule inhibitors designed to target cancer cells while sparing healthy tissue. A robust pipeline of therapeutic candidates is maintained to address multiple cancer targets, with ongoing clinical trials advancing these solutions to market. The biopharmaceutical sector is the primary focus, with an emphasis on innovative cancer treatment approaches.
- Annual Revenue$285.76 K (USD)-80.98as on Dec 31, 2025
- Net Profit-$12.6 M (USD)2.77as on Dec 31, 2025
- EBITDA-$13.21 M (USD)7.59as on Dec 31, 2025
- Total Equity Funding$113.17M (USD)
in 6 rounds
- Latest Funding Round$3.1M (USD), Post-IPO
Dec 2025
- InvestorsHHS
& 13 more
- Employee Count8
- Investments & Acquisitions
Products & Services of Aprea Therapeutics
Aprea Therapeutics offers a comprehensive portfolio of products and services, including DDR-Targeted Therapeutics and Small Molecule Inhibitors.
Therapeutics targeting DNA damage response in cancer.
Inhibitors designed to exploit cancer genetic mutations.
Funding Insights of Aprea Therapeutics
Aprea Therapeutics has successfully raised a total of $113.17M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.1 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $113.17M
- Total Rounds 6
- Last Round Post-IPO — $3.1M
- First Round $50.69M
(Mar 2016)
- Investors Count 14
All 6 funding rounds of Aprea Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2025 | $3.1M | Post-IPO | – | – | – |
| Mar 2024 | Post-IPO | – | – | ||
| Feb 2023 | $2M | Grant | – | – | |
| Feb 2019 | $5.7M | Series C | – | Janus Henderson Investors | – |
| Nov 2018 | $56.78M | Series C | – | Redmile Group, Janus Henderson Investors | |
| Mar 2016 | $50.69M | Series B | – | Versant Ventures, 5AM Ventures |
14 investors in total: 14 institutional.
Investors in Aprea Therapeutics
Aprea Therapeutics has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Janus Henderson Investors and Karolinska Development.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Exome Asset Management is focused on healthcare industry investments. | 2018 | exomeasset.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Early-stage life science investments in Sweden are targeted. | 2003 | karolinskadevelopment.com | Solna, Sweden | |
| healthcap.eu | ||||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Fundamentally-driven firm investing in micro-cap stocks with long and short strategies. | 2004 | nantahalapartners.com | New Canaan, United States | |
Manages long/short portfolios in publicly traded biotech and medical device firms. | 1999 | dafnacapital.com | Los Angeles, United States |
Investor details for Aprea Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Aprea Therapeutics
14 people are tracked at Aprea Therapeutics (3 in leadership, 10 in board & advisors, 1 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Ze’ev Weiss | Chief Business Advisor | Leadership |
John P. Hamill | Chief Financial Officer & SVP | Leadership |
Oren Gilad | President & Chief Executive Officer | Leadership |
John B. Henneman | Director | Board & advisors |
Michael Grissinger | Director | Board & advisors |
Rifat Pamukcu | Director | Board & advisors |
Richard Peters | Director | Board & advisors |
Bernd R. Seizinger | Director | Board & advisors |
Marc Duey | Director | Board & advisors |
Gabriela Gruia | Director | Board & advisors |
John B. Henneman Iii | Lead Independent Director | Board & advisors |
Chritian S. Schade | Chairman | Board & advisors |
Jean-Pierre Bizzari | Director | Board & advisors |
Nadeem Mirza | Senior Medical Advisor | Team |
Complete people profiles for Aprea Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aprea Therapeutics
Aprea Therapeutics is a publicly listed company on the NASDAQ with ticker symbol APRE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Oct 2019
- Listed onNASDAQ: APRE
- Listed entityAprea Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS03836J2015
- Share price$0.60 (+1.16% on the day) · 2026-10-13
- Market capitalisation$7.6M
- EPS (diluted, trailing year)$-1.08
- Volume (last session)136,916
Financials of Aprea Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $285,760 | -$12.6M | -$13.2M |
| 2024 | $1.5M | -$13.0M | -$14.3M |
| 2023 | $583,230 | -$14.3M | -$15.5M |
| 2022 | -$112.7M | -$37.2M | |
| 2021 | -$37.1M | -$37.2M |
Detailed financial statements for Aprea Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aprea Therapeutics
Aprea Therapeutics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Atrin Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule ATR pathway inhibitors and other therapeutics for multiple cancer indications. | atrinpharma.com | Doylestown, United States | 2011 | May 2022 | •••• |
Complete acquisition details for Aprea Therapeutics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aprea Therapeutics
5 dated milestones of Aprea Therapeutics across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Aprea Therapeutics is founded.
- Funding First funding round of $50.7M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Atrin Pharma.
- Funding Latest funding round, Post-IPO, of $3.1M.
Competitors of Aprea Therapeutics
Aprea Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Revolution Medicines, Blueprint Medicines and Syndax.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| revmed.com | 2014 | Redwood, United States | $326.29M | 181 | Cancer therapies are developed using selective pathway inhibitors. | |
| blueprintmedicines.com | 2008 | Cambridge, United States | $115M | 201 | Selective kinase inhibitors are developed for genomically defined cancers. | |
| syndax.com | 2005 | Waltham, United States | $198.29M | 107 | Targeted therapies for cancer treatment are developed. |
Detailed competitors of Aprea Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aprea Therapeutics
The website of Aprea Therapeutics (aprea.com) receives about 5.1K visits a month and ranks #3,297,251 among all websites worldwide, #4,344 in Biotechnology and Pharmaceuticals.
- Monthly visits5.1K
▼ 16.4% vs previous month
- Unique visitors2.5K
per month
- Global rank#3,297,251
among all websites
- Category rank#4,344
Health · Biotechnology and Pharmaceuticals
- Bounce rate44%
- Pages per visit1.7
- Average visit28 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Aprea Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| apricusbio.com | 100% | View details | |||
| apria.com | 59% | 459.8K | #80,305 | View details | |
| aacr.org | 58% | 321.9K | #142,787 | View details |
Top companies in Oncology
3 companies that operate in the same segment as Aprea Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aprea Therapeutics
Complete news archive for Aprea Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aprea Therapeutics
Aprea Therapeutics was founded in 2003 and raised its 1st funding round 13 years after it was founded.
Aprea Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Aprea Therapeutics is a funded company, having raised a total of $113.17M across 6 funding rounds to date. The company's 1st funding round was a Series B of $50.69M, raised on Mar 2016.
Aprea Therapeutics has 8 employees.
Annual revenue of Aprea Therapeutics is $285.76K as on Dec 31, 2025.
Aprea Therapeutics is engaged in the development of novel DNA Damage Response (DDR)-targeted cancer therapeutics. The company utilizes precision medicine to match treatments with specific genetic mutations in cancer, aiming to enhance effectiveness and reduce side effects. Their portfolio includes small molecule inhibitors designed to target cancer cells while sparing healthy tissue. A robust pipeline of therapeutic candidates is maintained to address multiple cancer targets, with ongoing clinical trials advancing these solutions to market. The biopharmaceutical sector is the primary focus, with an emphasis on innovative cancer treatment approaches.
Aprea Therapeutics's top competitors include Syndax, Revolution Medicines and Blueprint Medicines.
Aprea Therapeutics offers DDR-Targeted Therapeutics and Small Molecule Inhibitors.
Yes, Aprea Therapeutics is publicly traded on NASDAQ under the ticker symbol APRE.
Aprea Therapeutics has made 1 acquisition, including Atrin Pharma.
Aprea Therapeutics has 14 investors. Key investors include HHS, Janus Henderson Investors, Karolinska Development, Nantahala Capital Management, and DAFNA Capital Management.
Aprea Therapeutics operates through Aprea Therapeutics.